- Home
- PALI
PALI
Palisade Bio Inc.
as 05-09-2025 4:00pm EST
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 3.2M | IPO Year: | N/A |
| Target Price: | $23.00 | AVG Volume (30 days): | 92.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -10.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.60 - $8.57 | Next Earning Date: | 05-20-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Palisade Bio Inc. News
PALI Breaking Stock News: Dive into PALI Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases
GlobeNewswire
9 days ago
Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit
GlobeNewswire
a month ago
Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108
GlobeNewswire
2 months ago
Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108
GlobeNewswire
2 months ago
Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025
GlobeNewswire
2 months ago
Palisade Bio Participates in Virtual Investor “What This Means” Segment
GlobeNewswire
3 months ago
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada’s SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)
GlobeNewswire
3 months ago
Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Compare PALI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PALI Palisade Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.